Nicorandil Rivopharm

Nicorandil, the active ingredient in Nicorandil Rivopharm, is a nitrate vasodilator presented as an oral tablet for oral use. It treats stable angina pectoris in adult patients by improving myocardial blood flow and reducing cardiac workload.

GNH USA supplies Nicorandil Rivopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nicorandil acts on the coronary circulation and peripheral vasculature to relieve anginal symptoms.

Stable angina pectoris: reduces frequency and severity of chest pain episodes by lowering cardiac preload and afterload.

Nicorandil may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate, often transient. - Flushing: warmth and redness of the skin. - Dizziness or light‑headedness, especially on standing. - Nausea or abdominal discomfort. - Palpitations: awareness of heartbeats. - Mild hypotension: lower blood pressure without severe symptoms.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Exacerbation of angina or myocardial infarction. - Stevens‑Johnson syndrome or severe skin reactions. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes. - Life‑threatening arrhythmias.

Before initiating Nicorandil, consider the following safety measures.

Cardiovascular assessment: evaluate for recent myocardial infarction or unstable angina. Renal impairment: adjust therapy if severe kidney disease is present. Hepatic dysfunction: monitor liver function tests regularly. Concomitant nitrates or PDE5 inhibitors: avoid combined use due to risk of profound hypotension. Pregnancy and breastfeeding: safety not established; use only if benefits outweigh risks. Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Nicorandil can interact with several medication classes.

Major Interactions (Avoid): - Other nitrates: additive vasodilation may cause severe hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of marked blood pressure fall. - Potent vasodilators (e.g., hydralazine): may amplify hypotensive effects.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, ARBs, beta‑blockers): monitor blood pressure. - Diuretics: assess for volume depletion and orthostatic changes. - Calcium channel blockers: watch for additive cardiovascular effects. - Other anti‑anginal agents (e.g., ranolazine): evaluate overall symptom control. - Antiplatelet or anticoagulant therapy: monitor for bleeding tendencies.